CombiMatrix Cuts Spending in Q2 as Revenue Plunges 27 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — CombiMatrix today said that second-quarter revenue plunged 27 percent as R&D spending was cut nearly in half and net loss widened 5 percent.
 
Total receipts for the three months ended June 30 decreased to $1.3 million from $1.8 million during the same period last year.
 
Product sales declined 60 percent to $458,000; government contract revenue rose 20 percent to $680,000; and service revenue was up more than 230 percent to $199,000 from $60,000.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.